<Summary id="CDR0000334473" LegacyPDQID=""><SummaryMetaData><SummaryType>Treatment</SummaryType><SummaryAudience>Health professionals</SummaryAudience><SummaryLanguage>English</SummaryLanguage><SummaryDescription>Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are treated with chemotherapy or other drugs, stem cell transplant, supportive care, and targeted therapy. They include chronic myelomonocytic leukemia (CMML), juvenile myelomonocytic leukemia (JMML), and atypical chronic myeloid leukemia (aCML). Learn about the clinical features and treatment options for these leukemias.

</SummaryDescription><SummaryURL xref="https://www.cancer.gov/types/myeloproliferative/hp/mds-mpd-treatment-pdq">Myelodysplastic/Myeloproliferative Neoplasms (PDQ®): Treatment</SummaryURL><SummaryToggleURL xref="https://www.cancer.gov/types/myeloproliferative/patient/mds-mpd-treatment-pdq">Myelodysplastic/Myeloproliferative Neoplasms (PDQ®): Treatment</SummaryToggleURL><SummaryEditorialBoard ref="CDR0000028327">PDQ Adult Treatment Editorial Board</SummaryEditorialBoard><MainTopics><TermRef ref="CDR0000335173">myelodysplastic/myeloproliferative neoplasms</TermRef></MainTopics><SummaryAbstract><Para id="_136">This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of myelodysplastic/myeloproliferative neoplasms. It is intended as a resource to inform and assist clinicians in the care of their patients. It does not provide formal guidelines or recommendations for making health care decisions.</Para><Para id="_137">This summary is reviewed regularly and updated as necessary by the PDQ Adult Treatment Editorial Board, which is editorially independent of the National Cancer Institute (NCI). The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).</Para></SummaryAbstract><SummaryKeyWords><SummaryKeyWord>myelodysplastic/myeloproliferative neoplasms</SummaryKeyWord></SummaryKeyWords></SummaryMetaData><SummaryTitle>Myelodysplastic/Myeloproliferative Neoplasms Treatment  (PDQ®)–Health Professional Version</SummaryTitle><AltTitle TitleType="Browser">Myelodysplastic/Myeloproliferative Neoplasms Treatment (PDQ®)</AltTitle><AltTitle TitleType="CancerTypeHomePage">Myelodysplastic/Myeloproliferative Neoplasms Treatment</AltTitle><SummarySection id="_1"><SectMetaData><SpecificDiagnosis ref="CDR0000335173">myelodysplastic/myeloproliferative neoplasms</SpecificDiagnosis><SectionType>Prognosis--legacy</SectionType></SectMetaData><Title>General Information About Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN)</Title><SummarySection id="_130"><Title>Disease Overview</Title><Para id="_2">The myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are clonal myeloid disorders that have both dysplastic and proliferative features but are not properly classified as either myelodysplastic syndromes (MDS) or chronic myeloproliferative disorders (CMPD).<Reference refidx="1"/><Reference refidx="2"/><Reference refidx="3"/>  This category includes three major myeloid disorders: chronic myelomonocytic leukemia (CMML), juvenile myelomonocytic leukemia (JMML), and atypical chronic myeloid leukemia (aCML).  Myeloid disease that shows features of both MDS and CMPD but does not meet the criteria for any of the three major MDS/MPN entities is designated as myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-UC). The World Health Organization created the MDS/MPN category to provide a less restrictive view of myeloid disorders, which  in some instances clearly overlap.<Reference refidx="1"/><Reference refidx="2"/><Reference refidx="3"/></Para></SummarySection><SummarySection id="_127"><Title>Incidence and Mortality</Title><Para id="_4">The etiology of MDS/MPN is not known.  The incidence of MDS/MPN varies widely, ranging from approximately 3 per 100,000 individuals  older than 60 years annually for CMML to as few as 0.13 per 100,000 children from birth to 14 years annually for JMML.<Reference refidx="4"/> Reliable data concerning the incidence of aCML, a recently defined entity, are not available.  The incidence of MDS/MPN-UC is unknown.</Para></SummarySection><SummarySection id="_128"><Title>Histopathology</Title><Para id="_122">The pathophysiology of MDS/MPN involves abnormalities in the regulation of myeloid pathways for cellular proliferation, maturation, and survival.  Clinical symptoms result from the following complications:<Reference refidx="5"/></Para><ItemizedList id="_123" Style="bullet"><ListItem>Cytopenia(s).</ListItem><ListItem>Dysplastic cells that function abnormally.</ListItem><ListItem>Leukemic infiltration of various organ systems, especially the spleen and liver.</ListItem><ListItem>General constitutional symptoms, such as fever and malaise.</ListItem></ItemizedList><Para id="_138">Patients with MDS/MPN do not have a Philadelphia chromosome or a <GeneName>BCR</GeneName>::<GeneName>ABL1</GeneName> gene fusion.  </Para><Para id="_139">An international consortium has proposed uniform response criteria to be used in clinical trials because of the spectrum of presentations ranging from the myelodysplastic to the myeloproliferative.<Reference refidx="6"/></Para></SummarySection><ReferenceSection><Citation idx="1" PMID="27069254">Arber DA, Orazi A, Hasserjian R, et al.: The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127 (20): 2391-405, 2016.</Citation><Citation idx="2" PMID="19357394">Vardiman JW, Thiele J, Arber DA, et al.: The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114 (5): 937-51, 2009.</Citation><Citation idx="3" PMID="30054307">Loghavi S, Sui D, Wei P, et al.: Validation of the 2017 revision of the WHO chronic myelomonocytic leukemia categories. Blood Adv 2 (15): 1807-1816, 2018.</Citation><Citation idx="4" PMID="12239137" MedlineID="22224355">Vardiman JW, Harris NL, Brunning RD: The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100 (7): 2292-302, 2002.</Citation><Citation idx="5" PMID="10492067" MedlineID="99419816">Bain BJ: The relationship between the myelodysplastic syndromes and the myeloproliferative disorders. Leuk Lymphoma 34 (5-6): 443-9, 1999.</Citation><Citation idx="6" PMID="25624319">Savona MR, Malcovati L, Komrokji R, et al.: An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults. Blood 125 (12): 1857-65, 2015.</Citation></ReferenceSection></SummarySection><SummarySection id="_6"><SectMetaData><SpecificDiagnosis ref="CDR0000040361">chronic myelomonocytic leukemia</SpecificDiagnosis></SectMetaData><Title>Treatment of Chronic Myelomonocytic Leukemia</Title><SummarySection id="_7"><Title>Disease Overview    </Title><Para id="_8">The World Health Organization (WHO) classifies chronic myelomonocytic leukemia (CMML) as a myelodysplastic/myeloproliferative neoplasm (MDS/MPN).<Reference refidx="1"/> The WHO recognizes a dysplastic subtype and a proliferative subtype, with prognostic groups differentiated by the circulating white blood cell (WBC) count or the percentage of blasts in the bone marrow (higher percentage with worse prognosis).<Reference refidx="2"/></Para><Para id="_9">CMML is a clonal disorder of a bone marrow stem cell.  Monocytosis is a major defining feature.  CMML exhibits heterogenous clinical, hematological, and morphological features, varying from predominantly myelodysplastic to predominantly myeloproliferative. Evolution to acute myeloid leukemia (AML) portends a particularly poor prognosis.<Reference refidx="3"/></Para><Para id="_81">CMML is characterized pathologically by:<Reference refidx="4"/><Reference refidx="5"/></Para><ItemizedList id="_10" Style="bullet"><ListItem>Persistent monocytosis is greater than 1 × 10<Superscript>9</Superscript>/L in the peripheral blood.</ListItem><ListItem>No Philadelphia chromosome or <GeneName>BCR</GeneName>::<GeneName>ABL1</GeneName> gene fusion.</ListItem><ListItem>No <GeneName>PDGFRA</GeneName> and <GeneName>PDGFRB</GeneName>  rearrangement.</ListItem><ListItem>Fewer than 20% blasts in the blood or bone marrow (including monoblasts/promonocytes).</ListItem><ListItem>Dysplasia involving one or more myeloid lineages or, if myelodysplasia is absent or minimal, either an acquired clonal cytogenetic bone marrow abnormality or at least 3 months of persistent peripheral blood monocytosis, if all other causes are ruled out.</ListItem></ItemizedList><Para id="_82">Clinical features of CMML include:<Reference refidx="4"/><Reference refidx="5"/></Para><ItemizedList id="_11" Style="bullet"><ListItem>Fever, fatigue, night sweats, and weight loss. For more information, see <SummaryRef href="CDR0000062734" url="/about-cancer/treatment/side-effects/fatigue/fatigue-hp-pdq">Fatigue</SummaryRef>, <SummaryRef href="CDR0000062742" url="/about-cancer/treatment/side-effects/hot-flashes-hp-pdq">Hot Flashes and Night Sweats</SummaryRef>, and <SummaryRef href="CDR0000276584" url="/about-cancer/treatment/side-effects/appetite-loss/nutrition-hp-pdq">Nutrition in Cancer Care</SummaryRef>.</ListItem><ListItem>Infection.</ListItem><ListItem>Bleeding caused by  thrombocytopenia.</ListItem><ListItem>Hepatomegaly (in some patients).</ListItem><ListItem>Splenomegaly (in some patients). </ListItem><ListItem>In patients with a WBC count that is within reference range or slightly decreased, clinical features may be identical to MDS.</ListItem><ListItem>In patients with elevated WBC count, features are more like chronic myeloproliferative disorders, including more frequent splenomegaly and hepatomegaly.</ListItem></ItemizedList><Para id="_12">The median age at diagnosis of CMML is 65 to 75 years with a male predominance of 1.5 to 3.1.<Reference refidx="4"/><Reference refidx="5"/>  Because CMML is grouped with chronic myeloid leukemia in some epidemiologic surveys and with MDS in others, no reliable incidence data are available for CMML.<Reference refidx="6"/>  Although the specific etiology of CMML is unknown, exposure to occupational and environmental carcinogens, ionizing radiation, and cytotoxic agents has been associated in some cases.<Reference refidx="6"/></Para><Para id="_13">Morphologically, the disease is characterized by a persistent peripheral blood monocytosis (always &gt;1 × 10<Superscript>9</Superscript>/L) that may exceed 80 × 10<Superscript>9</Superscript>/L with monocytes typically accounting for more than 10% of the WBCs.<Reference refidx="4"/><Reference refidx="5"/>  Monocytes, though typically mature with an unremarkable morphology, can exhibit abnormal granulation, unusual nuclear lobation, or finely dispersed nuclear chromatin.<Reference refidx="7"/>  Fewer than 20% blasts are seen in the blood or bone marrow.  Neutrophilia occurs in nearly 50% of patients with neutrophil precursors (e.g., promyelocytes and  myelocytes) accounting for more than 10% of the WBCs.<Reference refidx="8"/>  Mild normocytic anemia is common.  Moderate thrombocytopenia is often present.  Bone marrow findings include:<Reference refidx="4"/><Reference refidx="5"/><Reference refidx="9"/><Reference refidx="10"/> </Para><ItemizedList id="_87" Style="bullet"><ListItem>Hypercellularity (75% of cases).</ListItem><ListItem>Blast count less than 20%.</ListItem><ListItem>Granulocytic proliferation (with dysgranulopoiesis).</ListItem><ListItem>Monocytic proliferation, dyserythropoiesis (e.g., megaloblastic changes, abnormal nuclear contours, ringed sideroblasts, etc.).</ListItem><ListItem>Micromegakaryocytes and/or megakaryocytes with abnormally lobated nuclei (as many as 80% of the cases).</ListItem><ListItem>Fibrosis (30% of the cases).</ListItem></ItemizedList><Para id="_14">Hepatosplenomegaly may be present.<Reference refidx="4"/><Reference refidx="5"/>  Autoimmune phenomena, including pyoderma gangrenosum, vasculitis, and idiopathic thrombocytopenia have been observed in CMML.<Reference refidx="11"/>  Care should be taken to identify cases of CMML with eosinophilia, a subtype of CMML, because of  its association with severe tissue damage secondary to eosinophil degranulation.  In CMML with eosinophilia, all criteria for CMML are present, and the eosinophil count in the peripheral blood is more than 1.5 × 10<Superscript>9</Superscript>/L.<Reference refidx="6"/>  </Para><Para id="_140">Recurrent somatic pathogenic variants have been identified in most patients with CMML, resulting in altered signaling molecules (especially <GeneName>NRAS</GeneName>, <GeneName>KRAS</GeneName>, <GeneName>JAK2</GeneName>, and <GeneName>SETBP1</GeneName>), epigenetic regulators (especially <GeneName>TET2</GeneName> and <GeneName>ASXL1</GeneName>), splicing factors (especially <GeneName>SRSF2</GeneName>), and transcription factors (especially <GeneName>RUNX1</GeneName>).<Reference refidx="12"/><Reference refidx="13"/><Reference refidx="14"/><Reference refidx="15"/> A CMML-specific prognostic scoring system can distinguish four risk groups based on the following factors:<Reference refidx="16"/></Para><OrderedList id="_141" Style="Arabic"><ListItem>Red blood cell transfusion dependency.</ListItem><ListItem>WBC count at least 13 × 10<Superscript>9</Superscript>/L.</ListItem><ListItem>Bone marrow blasts at least 5%.</ListItem><ListItem>Genetic risk group based on cytogenetics (trisomy 8, ≥3 abnormalities on karyotype, or chromosome 7 abnormalities are high risk), and pathogenic variants in <GeneName>ASXL1</GeneName>, <GeneName>NRAS</GeneName>, <GeneName>RUNX1</GeneName>, or <GeneName>SETBP1</GeneName>.</ListItem></OrderedList><Para id="_142">The best prognostic group has a median survival of more than 10 years with no leukemic evolution in the first decade of follow-up. The worst prognostic group has a  median survival of 20 months with a 50% evolution to AML by 2 years.<Reference refidx="16"/></Para><Para id="_15">  Prognostic factors associated with shorter survival include:<Reference refidx="17"/><Reference refidx="18"/>         </Para><ItemizedList id="_88" Style="bullet"><ListItem>Low hemoglobin level.</ListItem><ListItem>Low platelet count; high WBC, monocyte, and lymphocyte counts.</ListItem><ListItem>Presence of circulating immature myeloid cells.</ListItem><ListItem>High percentage of marrow blasts.</ListItem><ListItem>Low percentage of marrow erythroid cells.</ListItem><ListItem>Abnormal molecular genetic data.</ListItem><ListItem>High levels of serum lactate dehydrogenase and beta-2-microglobulin.</ListItem></ItemizedList><Para id="_89">Progression to acute leukemia occurs in approximately 15% to 20% of cases.<Reference refidx="17"/><Reference refidx="18"/></Para><Para id="_172">CPSS-Mol is a CMML-specific prognostic scoring system that incorporates molecular genetic data, especially pathogenic variants in <GeneName>RUNX1</GeneName>, <GeneName>NRAS</GeneName>, <GeneName>SETBP1</GeneName>, and <GeneName>ASXL1</GeneName>. This system distinguishes low-risk disease with median survivals longer than 10 years from high-risk disease with median survivals of 2 to 4 years.<Reference refidx="16"/></Para></SummarySection><SummarySection id="_16"><Title>Treatment Overview</Title><Para id="_161">CMML is a diagnosis typically made after age 70 years. The clinical course of CMML ranges from indolent or smoldering disease to an aggressive disease progression culminating in severe cytopenias or evolution to acute leukemia. Assessment of the risk factors and the pace of disease over time may help to distinguish patients who require therapy from those who would be best managed with a watchful waiting approach. Asymptomatic patients at low risk of progression may be best served by forgoing therapy.<Reference refidx="19"/><Reference refidx="20"/></Para><SummarySection id="_162"><Title>Allogeneic stem cell transplant (SCT)</Title><Para id="_163">Patients with high-risk disease who are young enough and fit enough may undergo allogeneic SCT. This represents the only potential cure for CMML. Hypomethylating agents like azacitidine and decitabine are usually given prior to allogeneic SCT for cytoreduction or to ameliorate cytopenias.<Reference refidx="21"/><Reference refidx="22"/> Retrospective reports that included small numbers of patients with CMML (range, 12–80) who underwent allogeneic SCT reported recurrence rates of  20% to 40% and 5-year overall survival (OS) rates of approximately 20% to 30%.<Reference refidx="23"/><Reference refidx="24"/><Reference refidx="25"/><Reference refidx="26"/><Reference refidx="27"/><Reference refidx="28"/>[<LOERef href="CDR0000810039" dictionary="NotSet" audience="Health professional">Level of evidence C3</LOERef>]</Para><Para id="_174">A retrospective review of 1,114 patients with CMML diagnosed between 2000 and 2014 included 384 patients who underwent allogeneic SCT.<Reference refidx="29"/> With a median follow-up of 51 to 78 months (in two data sets), allogeneic SCT in patients with low-risk CMML was detrimental, with a 5-year OS rates of 20% for patients who underwent allogeneic SCT and 42% for patients who did not undergo allogeneic SCT (<Emphasis>P</Emphasis> &lt; .001).<Reference refidx="29"/>[<LOERef href="CDR0000810035" dictionary="NotSet" audience="Health professional">Level of evidence C1</LOERef>] For patients with high-risk CMML, there was no statistically significant difference in 5-year OS rates among patients treated with or without allogeneic SCT (27% vs. 15%, respectively; <Emphasis>P</Emphasis> = .13).</Para></SummarySection><SummarySection id="_164"><Title>Hypomethylating agents</Title><Para id="_165">Two randomized prospective clinical trials compared the hypomethylating agent, azacitidine, with best supportive  care in patients with myelodysplastic syndromes (MDS). The trials involved large numbers of patients with MDS but also included small numbers of patients (fewer than 25) with CMML.<Reference refidx="30"/><Reference refidx="31"/> The overall response rates exceeded 60% for all patients who received azacitidine, but the data did not allow an assessment specifically for patients with CMML.<Reference refidx="30"/><Reference refidx="31"/>[<LOERef href="CDR0000810039" dictionary="NotSet" audience="Health professional">Level of evidence C3</LOERef>] Several phase II trials reported response rates of 30% to 60% for patients with CMML who received hypomethylating agents.<Reference refidx="32"/><Reference refidx="33"/><Reference refidx="34"/><Reference refidx="35"/><Reference refidx="36"/> Azacitidine and decitabine may reverse cytopenias, cytoreduce elevated WBC counts, reduce splenic size, and improve clinical symptoms (like decreased appetite or itching).</Para></SummarySection><SummarySection id="_166"><Title>Hydroxyurea</Title><Para id="_167">Hydroxyurea has been given for other diseases with chronic myeloproliferation, such as thrombocythemia and myelofibrosis. These applications suggest the use of hydroxyurea for CMML with leukocytosis, thrombocytosis, or splenomegaly.<Reference refidx="37"/> In a randomized prospective clinical trial of 105 patients with CMML, hydroxyurea (up to 4 g/day) was compared with etoposide.<Reference refidx="38"/> With a median follow-up of 11 months, the median OS was 20 months in patients who received hydroxyurea and 9 months in patients who received etoposide (<Emphasis>P</Emphasis> &lt; .0001).<Reference refidx="38"/>[<LOERef href="CDR0000810017" dictionary="NotSet" audience="Health professional">Level of evidence A1</LOERef>]</Para></SummarySection><SummarySection id="_168"><Title>Hypomethylating agent versus hydroxyurea</Title><Para id="_169">In a prospective randomized trial, 170 patients with newly diagnosed advanced CMML received intravenous decitabine or hydroxyurea (1–4 g/day). With a median follow-up of 17.5 months, there was no statistically significant difference in event-free survival (12.1 months for patients who received decitabine and 10.3 months for patients who received hydroxyurea; hazard ratio, 0.83; 95% confidence interval [CI], 0.59–1.16; <Emphasis>P</Emphasis> = .27). There was also no statistically significant difference in median OS (16.3 months for patients who received decitabine and 21.9 months for patients who received hydroxyurea; <Emphasis>P</Emphasis> = .67).<Reference refidx="39"/>[<LOERef href="CDR0000810017" dictionary="NotSet" audience="Health professional">Level of evidence A1</LOERef>] Although decitabine reduced CMML progression or transformation to AML by 38% compared with hydroxyurea, this was offset by a 55% increase in deaths that were not caused by progression (the deaths were usually related to infection). There are no data to suggest that systematic antibiotic prophylaxis would have helped the patients who received decitabine.</Para></SummarySection><SummarySection id="_170"><Title>Other regimens</Title><Para id="_171">In a phase II trial, 13 hypomethylating agent–naive patients with high-risk CMML were treated with azacitidine or decitabine plus venetoclax. With a median follow-up of 14.1 months, the overall response rate was 85% (11 of 13 patients), including two with complete response and a median duration of response of 17.9 months.<Reference refidx="40"/><Reference refidx="41"/>[<LOERef href="CDR0000810039" dictionary="NotSet" audience="Health professional">Level of evidence C3</LOERef>] Six of these patients underwent subsequent allogeneic SCT.</Para><Para id="_182"> A retrospective study included 21 patients with high-risk CMML who received cladribine plus low-dose cytarabine alternating with azacitidine or decitabine. The patients had an objective response rate of 33% (50% in patients with hypomethylating agent–naive CMML and 23% in patients with hypomethylating agent–failure CMML).<Reference refidx="41"/>[<LOERef href="CDR0000810039" dictionary="NotSet" audience="Health professional">Level of evidence C3</LOERef>] </Para><Para id="_173">A phase I/II study of 23 patients with mostly high-risk MDS and greater than 5% marrow blast cells involved 10 patients with CMML. All patients received azacitidine plus venetoclax. With a median follow-up of 13.2 months, the overall response rate was 87% (95% CI, 66%–97%).<Reference refidx="42"/>[<LOERef href="CDR0000810039" dictionary="NotSet" audience="Health professional">Level of evidence C3</LOERef>]</Para></SummarySection></SummarySection><SummarySection id="_TrialSearch_6_sid_2"><Title>Current Clinical Trials</Title><Para id="_TrialSearch_6_22">Use our <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials-search/advanced">advanced clinical trial search</ExternalRef> to find NCI-supported cancer clinical trials that are now enrolling patients. The search can be narrowed by location of the trial, type of treatment, name of the drug, and other criteria. <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials">General information</ExternalRef> about clinical trials is also available.</Para></SummarySection><ReferenceSection><Citation idx="1" PMID="18480833">Orazi A, Germing U: The myelodysplastic/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features. Leukemia 22 (7): 1308-19, 2008.</Citation><Citation idx="2" PMID="27069254">Arber DA, Orazi A, Hasserjian R, et al.: The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127 (20): 2391-405, 2016.</Citation><Citation idx="3" PMID="17606449">Germing U, Strupp C, Knipp S, et al.: Chronic myelomonocytic leukemia in the light of the WHO proposals. Haematologica 92 (7): 974-7, 2007.</Citation><Citation idx="4" PMID="15087071">Onida F, Beran M: Chronic myelomonocytic leukemia: myeloproliferative variant. Curr Hematol Rep 3 (3): 218-26, 2004.</Citation><Citation idx="5" PMID="18548091">Emanuel PD: Juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia. Leukemia 22 (7): 1335-42, 2008.</Citation><Citation idx="6" PMID="9542325" MedlineID="98203448">Aul C, Bowen DT, Yoshida Y: Pathogenesis, etiology and epidemiology of myelodysplastic syndromes. Haematologica 83 (1): 71-86, 1998.</Citation><Citation idx="7" PMID="8722681" MedlineID="96303400">Kouides PA, Bennett JM: Morphology and classification of the myelodysplastic syndromes and their pathologic variants. Semin Hematol 33 (2): 95-110, 1996.</Citation><Citation idx="8" PMID="7986717" MedlineID="95078144">Bennett JM, Catovsky D, Daniel MT, et al.: The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French-American-British Cooperative Leukaemia Group. Br J Haematol 87 (4): 746-54, 1994.</Citation><Citation idx="9" PMID="8477199" MedlineID="93237810">Michaux JL, Martiat P: Chronic myelomonocytic leukaemia (CMML)--a myelodysplastic or myeloproliferative syndrome? Leuk Lymphoma 9 (1-2): 35-41, 1993.</Citation><Citation idx="10" PMID="1592101" MedlineID="92275062">Maschek H, Georgii A, Kaloutsi V, et al.: Myelofibrosis in primary myelodysplastic syndromes: a retrospective study of 352 patients. Eur J Haematol 48 (4): 208-14, 1992.</Citation><Citation idx="11" PMID="12533032" MedlineID="22420465">Saif MW, Hopkins JL, Gore SD: Autoimmune phenomena in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. Leuk Lymphoma 43 (11): 2083-92, 2002.</Citation><Citation idx="12" PMID="22919025">Meggendorfer M, Roller A, Haferlach T, et al.: SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML). Blood 120 (15): 3080-8, 2012.</Citation><Citation idx="13" PMID="19797729">Kosmider O, Gelsi-Boyer V, Ciudad M, et al.: TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia. Haematologica 94 (12): 1676-81, 2009.</Citation><Citation idx="14" PMID="24970933">Malcovati L, Papaemmanuil E, Ambaglio I, et al.: Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia. Blood 124 (9): 1513-21, 2014.</Citation><Citation idx="15" PMID="24695057">Patnaik MM, Itzykson R, Lasho TL, et al.: ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients. Leukemia 28 (11): 2206-12, 2014.</Citation><Citation idx="16" PMID="27385790">Elena C, Gallì A, Such E, et al.: Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia. Blood 128 (10): 1408-17, 2016.</Citation><Citation idx="17" PMID="11806985" MedlineID="21665804">Onida F, Kantarjian HM, Smith TL, et al.: Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood 99 (3): 840-9, 2002.</Citation><Citation idx="18" PMID="15359628">Germing U, Kündgen A, Gattermann N: Risk assessment in chronic myelomonocytic leukemia (CMML). Leuk Lymphoma 45 (7): 1311-8, 2004.</Citation><Citation idx="19" PMID="30367269">Hunter AM, Zhang L, Padron E: Current Management and Recent Advances in the Treatment of Chronic Myelomonocytic Leukemia. Curr Treat Options Oncol 19 (12): 67, 2018.</Citation><Citation idx="20" PMID="31736132">Patnaik MM, Tefferi A: Chronic Myelomonocytic leukemia: 2020 update on diagnosis, risk stratification and management. Am J Hematol 95 (1): 97-115, 2020.</Citation><Citation idx="21" PMID="26343946">Kongtim P, Popat U, Jimenez A, et al.: Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Progression-Free Survival for Patients with Chronic Myelomonocytic Leukemia. Biol Blood Marrow Transplant 22 (1): 47-53, 2016.</Citation><Citation idx="22" PMID="28486043">Sekeres MA, Othus M, List AF, et al.: Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117. J Clin Oncol 35 (24): 2745-2753, 2017.</Citation><Citation idx="23" PMID="16604096">Elliott MA, Tefferi A, Hogan WJ, et al.: Allogeneic stem cell transplantation and donor lymphocyte infusions for chronic myelomonocytic leukemia. Bone Marrow Transplant 37 (11): 1003-8, 2006.</Citation><Citation idx="24" PMID="18997830">Ocheni S, Kröger N, Zabelina T, et al.: Outcome of allo-SCT for chronic myelomonocytic leukemia. Bone Marrow Transplant 43 (8): 659-61, 2009.</Citation><Citation idx="25" PMID="20098454">Krishnamurthy P, Lim ZY, Nagi W, et al.: Allogeneic haematopoietic SCT for chronic myelomonocytic leukaemia: a single-centre experience. Bone Marrow Transplant 45 (10): 1502-7, 2010.</Citation><Citation idx="26" PMID="20932924">Eissa H, Gooley TA, Sorror ML, et al.: Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia: relapse-free survival is determined by karyotype and comorbidities. Biol Blood Marrow Transplant 17 (6): 908-15, 2011.</Citation><Citation idx="27" PMID="23320648">Park S, Labopin M, Yakoub-Agha I, et al.: Allogeneic stem cell transplantation for chronic myelomonocytic leukemia: a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. Eur J Haematol 90 (5): 355-64, 2013.</Citation><Citation idx="28" PMID="26212516">Symeonidis A, van Biezen A, de Wreede L, et al.: Achievement of complete remission predicts outcome of allogeneic haematopoietic stem cell transplantation in patients with chronic myelomonocytic leukaemia. A study of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation. Br J Haematol 171 (2): 239-246, 2015.</Citation><Citation idx="29" PMID="35667047">Robin M, de Wreede LC, Padron E, et al.: Role of allogeneic transplantation in chronic myelomonocytic leukemia: an international collaborative analysis. Blood 140 (12): 1408-1418, 2022.</Citation><Citation idx="30" PMID="12011120" MedlineID="22007249">Silverman LR, Demakos EP, Peterson BL, et al.: Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 20 (10): 2429-40, 2002.</Citation><Citation idx="31" PMID="19230772">Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al.: Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 10 (3): 223-32, 2009.</Citation><Citation idx="32" PMID="21828134">Braun T, Itzykson R, Renneville A, et al.: Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial. Blood 118 (14): 3824-31, 2011.</Citation><Citation idx="33" PMID="24569776">Drummond MW, Pocock C, Boissinot M, et al.: A multi-centre phase 2 study of azacitidine in chronic myelomonocytic leukaemia. Leukemia 28 (7): 1570-2, 2014.</Citation><Citation idx="34" PMID="26752680">Tantravahi SK, Szankasi P, Khorashad JS, et al.: A phase II study of the efficacy, safety, and determinants of response to 5-azacitidine (Vidaza®) in patients with chronic myelomonocytic leukemia. Leuk Lymphoma 57 (10): 2441-4, 2016.</Citation><Citation idx="35" PMID="28607470">Santini V, Allione B, Zini G, et al.: A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia. Leukemia 32 (2): 413-418, 2018.</Citation><Citation idx="36" PMID="30964202">Coston T, Pophali P, Vallapureddy R, et al.: Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patients. Am J Hematol 94 (7): 767-779, 2019.</Citation><Citation idx="37" PMID="12057067" MedlineID="22052728">Bennett JM: Chronic myelomonocytic leukemia. Curr Treat Options Oncol 3 (3): 221-3, 2002.</Citation><Citation idx="38" PMID="8839839" MedlineID="96437023">Wattel E, Guerci A, Hecquet B, et al.: A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Groupe Français des Myélodysplasies and European CMML Group. Blood 88 (7): 2480-7, 1996.</Citation><Citation idx="39" PMID="36455187">Itzykson R, Santini V, Thepot S, et al.: Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia: Results of a Randomized Phase III Trial Within the EMSCO Network. J Clin Oncol 41 (10): 1888-1897, 2023.</Citation><Citation idx="40" PMID="33846541">Montalban-Bravo G, Hammond D, DiNardo CD, et al.: Activity of venetoclax-based therapy in chronic myelomonocytic leukemia. Leukemia 35 (5): 1494-1499, 2021.</Citation><Citation idx="41" PMID="36458426">Bazinet A, Darbaniyan F, Kadia TM, et al.: A retrospective study of cladribine and low-dose cytarabine-based regimens for the treatment of chronic myelomonocytic leukemia and secondary acute myeloid leukemia. Cancer 129 (4): 560-568, 2023.</Citation><Citation idx="42" PMID="36063832">Bazinet A, Darbaniyan F, Jabbour E, et al.: Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1-2 study. Lancet Haematol 9 (10): e756-e765, 2022.</Citation></ReferenceSection></SummarySection><SummarySection id="_26"><SectMetaData><SpecificDiagnosis ref="CDR0000038439">juvenile myelomonocytic leukemia</SpecificDiagnosis></SectMetaData><Title>Treatment of Juvenile Myelomonocytic Leukemia</Title><Para id="_189">For more information, see <SummaryRef href="CDR0000810728" url="/types/leukemia/hp/child-aml-treatment-pdq/childhood-jmml-treatment-pdq">Juvenile Myelomonocytic Leukemia Treatment</SummaryRef>.</Para></SummarySection><SummarySection id="_50"><SectMetaData><SpecificDiagnosis ref="CDR0000335175">atypical chronic myeloid leukemia, BCR-ABL1 negative</SpecificDiagnosis></SectMetaData><Title>Treatment of Atypical Chronic Myeloid Leukemia</Title><SummarySection id="_51"><Title>Disease Overview</Title><Para id="_52">Atypical chronic myeloid leukemia (aCML) is a leukemic disorder that exhibits both myelodysplastic and myeloproliferative features at the time of diagnosis.  </Para><Para id="_84">Atypical CML is characterized pathologically by:<Reference refidx="1"/></Para><ItemizedList id="_53" Style="bullet"><ListItem>Peripheral blood leukocytosis with increased numbers of mature and immature neutrophils.</ListItem><ListItem>Prominent dysgranulopoiesis.</ListItem><ListItem>No Philadelphia chromosome or <GeneName>BCR</GeneName>::<GeneName>ABL1</GeneName> gene fusion.</ListItem><ListItem>Neutrophil precursors (e.g.,  promyelocytes, myelocytes, and metamyelocytes) accounting for more than 10% of white blood cells.</ListItem><ListItem>Minimal absolute basophilia with basophils accounting for less than 2% of white blood cells.</ListItem><ListItem>Absolute monocytosis with monocytes typically account for less than 10% of white blood cells.</ListItem><ListItem>Hypercellular bone marrow with granulocytic proliferation and granulocytic dysplasia.</ListItem><ListItem>Fewer than 20% blasts in the blood or bone marrow.</ListItem><ListItem>Thrombocytopenia.
</ListItem></ItemizedList><Para id="_85">Clinical features of aCML include:<Reference refidx="1"/><Reference refidx="2"/><Reference refidx="3"/><Reference refidx="4"/></Para><ItemizedList id="_54" Style="bullet"><ListItem>Anemia. For more information on anemia, see <SummaryRef href="CDR0000062734" url="/about-cancer/treatment/side-effects/fatigue/fatigue-hp-pdq">Fatigue</SummaryRef>.</ListItem><ListItem>Thrombocytopenia.</ListItem><ListItem>Splenomegaly (in 75% of cases).</ListItem></ItemizedList><Para id="_92">Although cytogenetic abnormalities are found in as many as 80% of the patients with aCML, none is specific.<Reference refidx="1"/><Reference refidx="2"/><Reference refidx="3"/><Reference refidx="5"/>  No Philadelphia chromosome or <GeneName>BCR</GeneName>::<GeneName>ABL1</GeneName> gene fusion is present.</Para><Para id="_55">The exact incidence of aCML is unknown.  The median age at the time of diagnosis of this rare leukemic disorder is in the seventh or eighth decade of life.<Reference refidx="1"/><Reference refidx="2"/><Reference refidx="3"/></Para><Para id="_56">Morphologically, aCML is characterized by myelodysplasia associated with bone marrow and peripheral blood patterns similar to chronic myeloid leukemia, but cytogenetically it lacks a Philadelphia chromosome or <GeneName>BCR</GeneName>::<GeneName>ABL1</GeneName> gene fusion.<Reference refidx="1"/>  The white blood cell count in the peripheral blood is variable.  Median values range from 35 × 10<Superscript>9</Superscript>/L to 96 × 10<Superscript>9</Superscript>/L, and some patients may have white blood cell counts greater  than 300 × 10<Superscript>9</Superscript>/L.<Reference refidx="1"/><Reference refidx="2"/><Reference refidx="3"/><Reference refidx="5"/>  Blasts in the peripheral blood typically account for less than 5% of the white blood cells.  Immature neutrophils usually total 10% to 20% or more.<Reference refidx="1"/>  The percentage of monocytes is rarely more than 10%. Minimal basophilia may be present.<Reference refidx="1"/><Reference refidx="2"/><Reference refidx="3"/><Reference refidx="5"/>    Nuclear abnormalities, such as acquired Pelger-Huët anomaly, may be seen in the neutrophils.  Moderate anemia (often showing changes indicative of dyserythropoiesis) and thrombocytopenia are common.<Reference refidx="1"/><Reference refidx="2"/><Reference refidx="3"/><Reference refidx="4"/>  Bone marrow findings include: <Reference refidx="1"/><Reference refidx="2"/><Reference refidx="3"/><Reference refidx="5"/> </Para><ItemizedList id="_91" Style="bullet"><ListItem>Granulocytic hypercellularity.</ListItem><ListItem>Blast count less than 20%.</ListItem><ListItem>Dysgranulopoiesis</ListItem><ListItem>Megakaryocytic dysplasia.</ListItem><ListItem>Erythroid precursors accounting for more than 30% of marrow cells with dyserythropoiesis present (in some cases).</ListItem></ItemizedList><Para id="_58">The median survival times for aCML are reported to be less than 20 months, and thrombocytopenia and marked anemia are poor prognostic factors.<Reference refidx="1"/><Reference refidx="2"/>   Atypical CML evolves to acute leukemia in approximately 25% to 40% of patients.<Reference refidx="1"/><Reference refidx="3"/>  In the remaining patients, fatal complications include resistant leukocytosis, anemia, thrombocytopenia, hepatosplenomegaly, cerebral bleeding associated with thrombocytopenia, and infection.<Reference refidx="3"/><Reference refidx="4"/> </Para></SummarySection><SummarySection id="_59"><Title>Treatment Overview</Title><Para id="_60">
The optimal treatment of aCML is uncertain because of  the rare incidence of this chronic leukemic disorder. Treatment with hydroxyurea may lead to short-lived partial remissions of 2 to 4 months in duration.<Reference refidx="4"/> Atypical CML appears to  respond poorly to treatment with interferon alfa.<Reference refidx="4"/> 
</Para></SummarySection><SummarySection id="_TrialSearch_50_sid_4"><Title>Current Clinical Trials</Title><Para id="_TrialSearch_50_22">Use our <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials-search/advanced">advanced clinical trial search</ExternalRef> to find NCI-supported cancer clinical trials that are now enrolling patients. The search can be narrowed by location of the trial, type of treatment, name of the drug, and other criteria. <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials">General information</ExternalRef> about clinical trials is also available.</Para></SummarySection><ReferenceSection><Citation idx="1" PMID="18480833">Orazi A, Germing U: The myelodysplastic/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features. Leukemia 22 (7): 1308-19, 2008.</Citation><Citation idx="2" PMID="10847463" MedlineID="20304076">Hernández JM, del Cañizo MC, Cuneo A, et al.: Clinical, hematological and cytogenetic characteristics of atypical chronic myeloid leukemia. Ann Oncol 11 (4): 441-4, 2000.</Citation><Citation idx="3" PMID="9168433" MedlineID="97311718">Costello R, Sainty D, Lafage-Pochitaloff M, et al.: Clinical and biological aspects of Philadelphia-negative/BCR-negative chronic myeloid leukemia. Leuk Lymphoma 25 (3-4): 225-32, 1997.</Citation><Citation idx="4" PMID="11387365" MedlineID="21281043">Kurzrock R, Bueso-Ramos CE, Kantarjian H, et al.: BCR rearrangement-negative chronic myelogenous leukemia revisited. J Clin Oncol 19 (11): 2915-26, 2001.</Citation><Citation idx="5" PMID="7986717" MedlineID="95078144">Bennett JM, Catovsky D, Daniel MT, et al.: The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French-American-British Cooperative Leukaemia Group. Br J Haematol 87 (4): 746-54, 1994.</Citation></ReferenceSection></SummarySection><SummarySection id="_64"><SectMetaData><SpecificDiagnosis ref="CDR0000335177">myelodysplastic/myeloproliferative neoplasm, unclassifiable</SpecificDiagnosis></SectMetaData><Title>Treatment of MDS/MPN, Unclassifiable</Title><SummarySection id="_65"><Title>Disease Overview</Title><Para id="_66">Myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-UC) (also known as mixed myeloproliferative/myelodysplastic syndrome, unclassifiable and overlap syndrome, unclassifiable) shows features of both myeloproliferative disease and myelodysplastic disease but does not meet the criteria for any of the other MDS/MPN entities.<Reference refidx="1"/></Para><Para id="_86">Diagnostic criteria for MDS/MPN-UC can be either:<Reference refidx="1"/></Para><OrderedList id="_67" Style="Arabic"><ListItem>	The combination of four sets of criteria (a–d):<OrderedList id="_68" Style="LAlpha"><ListItem>Clinical, laboratory, and morphological features of myelodysplastic syndrome (MDS) (e.g., refractory anemia, refractory anemia with ringed sideroblasts, refractory cytopenia with multilineage dysplasia, and refractory anemia with excess of blasts) with fewer than 20% blasts in the blood and bone marrow.  For more information on anemia, see <SummaryRef href="CDR0000062734" url="/about-cancer/treatment/side-effects/fatigue/fatigue-hp-pdq">Fatigue</SummaryRef>.</ListItem><ListItem>Prominent myeloproliferative features, e.g. platelet count greater than 600 × 10<Superscript>9</Superscript>/L associated with megakaryocytic proliferation, or white blood cell count greater than 13.0 × 10<Superscript>9</Superscript>/L with or without splenomegaly. </ListItem><ListItem>No  history of an underlying chronic myeloproliferative disorder (CMPD), MDS, or recent cytotoxic or growth factor therapy that could cause the myelodysplastic or myeloproliferative features.</ListItem><ListItem>No Philadelphia chromosome or <GeneName>BCR</GeneName>::<GeneName>ABL1</GeneName> gene fusion, del(5q), t(3;3)(q21;q26), or inv(3)(q21q26).</ListItem></OrderedList></ListItem><ListItem>	Mixed myeloproliferative and myelodysplastic features that cannot be assigned to any other category of MDS, CMPD, or MDS/MPN.</ListItem></OrderedList><ItemizedList id="_69" Style="bullet"><ListTitle>Clinical characteristics of MDS/MPN-UC include:</ListTitle><ListItem>Features of both MDS and CMPD.</ListItem><ListItem>Hepatomegaly.</ListItem><ListItem>Splenomegaly.</ListItem></ItemizedList><Para id="_70">The incidence and etiology of MDS/MPN-UC are unknown.</Para><Para id="_71">Laboratory features typically include anemia and dimorphic erythrocytes on the peripheral blood smear.<Reference refidx="1"/>  Thrombocytosis (platelet count &gt;600 × 10<Superscript>9</Superscript>/L) or leukocytosis (white blood cell count &gt;13 × 10<Superscript>9</Superscript>/L) are present.  Neutrophils may exhibit dysplastic features, and giant or hypogranular platelets may be present.  Blasts make up less than  20% of the white blood cells and of the nucleated cells of the bone marrow.  The bone marrow is hypercellular and may exhibit proliferation in any or all of the myeloid lineages. Dysplastic features are present in at least one cell line.<Reference refidx="1"/></Para><Para id="_72">No cytogenetic or molecular findings are available that are specific for MDS/MPN-UC.  In one small series, six of nine patients (those with ringed sideroblasts associated with marked thrombocytosis [RARS-T]) had <GeneName>JAK2</GeneName> V617F variants, which caused constitutive activation of the JAK2 tyrosine kinase. This <GeneName>JAK2</GeneName> pathogenic variant is also commonly observed in patients with polycythemia vera, essential thrombocythemia, and idiopathic myelofibrosis.<Reference refidx="2"/> Because of  its rare occurrence, the prognosis and predictive factors are unknown.<Reference refidx="1"/> </Para></SummarySection><SummarySection id="_73"><Title>Treatment Overview</Title><Para id="_74">
Adult patients with MDS/MPN associated with platelet-derived growth factor receptor gene rearrangements are candidates for imatinib mesylate at standard dosages.<Reference refidx="3"/> Because of its rare occurrence, the literature only minimally addresses other treatment options for MDS/MPN-UC.  Supportive care involves treating cytopenias and infection as necessary.</Para></SummarySection><SummarySection id="_TrialSearch_64_sid_5"><Title>Current Clinical Trials</Title><Para id="_TrialSearch_64_22">Use our <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials-search/advanced">advanced clinical trial search</ExternalRef> to find NCI-supported cancer clinical trials that are now enrolling patients. The search can be narrowed by location of the trial, type of treatment, name of the drug, and other criteria. <ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials">General information</ExternalRef> about clinical trials is also available.</Para></SummarySection><ReferenceSection><Citation idx="1" PMID="18480833">Orazi A, Germing U: The myelodysplastic/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features. Leukemia 22 (7): 1308-19, 2008.</Citation><Citation idx="2" PMID="16741247">Szpurka H, Tiu R, Murugesan G, et al.: Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation. Blood 108 (7): 2173-81, 2006.</Citation><Citation idx="3">GLEEVEC - imatinib mesylate tablet. Novartis Pharmaceuticals Corporation, 2020. <ExternalRef xref="https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf">Available online</ExternalRef>. Last accessed February 18, 2025.</Citation></ReferenceSection></SummarySection><SummarySection id="_78"><SectMetaData><SectionType>Changes to summary</SectionType></SectMetaData><Title>Latest Updates to This Summary (05/14/2025)</Title><Para id="_79">The PDQ cancer information summaries are reviewed regularly and updated as
new information becomes available.  This section describes the latest
changes made to this summary as of the date above.</Para><Para id="_190">Editorial changes were made to this summary.</Para><Para id="_disclaimerHP_3">This summary is written and maintained by the <ExternalRef xref="https://www.cancer.gov/publications/pdq/editorial-boards/adult-treatment">PDQ Adult Treatment Editorial Board</ExternalRef>, which is
editorially independent of NCI.  The summary reflects an independent review of
the literature and does not represent a policy statement of NCI or NIH.  More
information about summary policies and the role of the PDQ Editorial Boards  in
maintaining the PDQ summaries can be found on the <SummaryRef href="CDR0000334473#_AboutThis_1" url="/types/myeloproliferative/hp/mds-mpd-treatment-pdq">About This PDQ Summary</SummaryRef> and <ExternalRef xref="https://www.cancer.gov/publications/pdq">PDQ® Cancer Information for Health Professionals</ExternalRef> pages.
</Para></SummarySection><SummarySection id="_AboutThis_1"><Title>About This PDQ Summary</Title><SummarySection id="_AboutThis_2"><Title>Purpose of This Summary</Title><Para id="_AboutThis_3">This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of myelodysplastic/myeloproliferative neoplasms. It is intended as a resource to inform and assist clinicians in the care of their patients.  It does not provide formal guidelines or recommendations for making health care decisions.</Para></SummarySection><SummarySection id="_AboutThis_4"><Title>Reviewers and Updates</Title><Para id="_AboutThis_5">This summary is reviewed regularly and updated as necessary by the <ExternalRef xref="https://www.cancer.gov/publications/pdq/editorial-boards/adult-treatment">PDQ Adult Treatment Editorial Board</ExternalRef>, which is editorially independent of the National Cancer Institute (NCI).  The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).</Para><Para id="_AboutThis_22"> Board members review recently published articles each month to determine whether an article should:</Para><ItemizedList id="_AboutThis_6" Style="bullet"><ListItem>be discussed at a meeting,</ListItem><ListItem>be cited with text, or</ListItem><ListItem>replace or update an existing article that is already cited.</ListItem></ItemizedList><Para id="_AboutThis_7">Changes to the summaries are made through a consensus process in which Board members evaluate the strength of the evidence in  the published articles and determine how the article should be included in the summary.</Para><Para>The lead reviewers for Myelodysplastic/Myeloproliferative Neoplasms Treatment are:</Para><ItemizedList Style="bullet"><ListItem>Aaron Gerds, MD (Cleveland Clinic Taussig Cancer Institute)</ListItem><ListItem>Eric J. Seifter, MD (Johns Hopkins University)</ListItem></ItemizedList><Para id="_AboutThis_9">Any comments or questions about the summary content should be submitted to Cancer.gov through the NCI website's <ExternalRef xref="https://www.cancer.gov/contact/email-us">Email Us</ExternalRef>. Do not contact the individual Board Members with questions or comments about the summaries. Board members will not respond to individual inquiries.</Para></SummarySection><SummarySection id="_AboutThis_10"><Title>Levels of Evidence</Title><Para id="_AboutThis_11">Some of the reference citations in this summary are accompanied by a level-of-evidence designation. These designations are intended to help readers assess the strength of the evidence supporting the use of specific interventions or approaches. The PDQ Adult Treatment Editorial Board uses a <SummaryRef href="CDR0000062796" url="/publications/pdq/levels-evidence/treatment">formal evidence ranking system</SummaryRef> in developing its level-of-evidence designations.</Para></SummarySection><SummarySection id="_AboutThis_12"><Title>Permission to Use This Summary</Title><Para id="_AboutThis_13">PDQ is a registered trademark. Although the content of PDQ documents can be used freely as text, it cannot be identified as an NCI PDQ cancer information summary unless it is presented in its entirety and is regularly updated. However, an author would be permitted to write a sentence such as “NCI’s PDQ cancer information summary about breast cancer prevention states the risks succinctly: [include excerpt from the summary].”</Para><Para id="_AboutThis_14">The preferred citation for this PDQ summary is:</Para><Para id="_AboutThis_15">PDQ® Adult Treatment Editorial Board. PDQ Myelodysplastic/Myeloproliferative Neoplasms Treatment. Bethesda, MD: National Cancer Institute. Updated  &lt;MM/DD/YYYY&gt;. Available at: <ExternalRef xref="https://www.cancer.gov/types/myeloproliferative/hp/mds-mpd-treatment-pdq">https://www.cancer.gov/types/myeloproliferative/hp/mds-mpd-treatment-pdq</ExternalRef>.  Accessed &lt;MM/DD/YYYY&gt;. [PMID: 26389321]</Para><Para id="_AboutThis_16">Images in this summary are used with permission of the author(s), artist, and/or publisher for use within the PDQ summaries only. Permission to use images outside the context of PDQ information must be obtained from the owner(s) and cannot be granted by  the National Cancer Institute. Information about using the illustrations in this summary, along with many other cancer-related images, is available in <ExternalRef xref="https://visualsonline.cancer.gov/">Visuals Online</ExternalRef>, a collection of over 2,000 scientific images.

</Para></SummarySection><SummarySection id="_AboutThis_17"><Title>Disclaimer</Title><Para id="_AboutThis_18">Based on the strength of the available evidence, treatment options may be described as either “standard” or “under clinical evaluation.” These classifications should not be used as a basis for insurance reimbursement determinations. More information on insurance coverage is available on Cancer.gov on the <ExternalRef xref="https://www.cancer.gov/about-cancer/managing-care">Managing Cancer Care</ExternalRef> page.</Para></SummarySection><SummarySection id="_AboutThis_20"><Title>Contact Us</Title><Para id="_AboutThis_21">More information about contacting us or receiving help with the Cancer.gov website can be found on our <ExternalRef xref="https://www.cancer.gov/contact">Contact Us for Help</ExternalRef> page. Questions can also be submitted to Cancer.gov through the website’s <ExternalRef xref="https://www.cancer.gov/contact/email-us">Email Us</ExternalRef>.</Para></SummarySection></SummarySection><DateFirstPublished>2003-09-24</DateFirstPublished><DateLastModified>2025-05-14</DateLastModified></Summary>
